A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...
ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...
CARs, chimeric antigen receptors; CD, cluster of differentiation; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; IL, interleukin; NK, natural killer; PD1 ...
Priority review for ravulizumab in IgA nephropathy could establish the first C5 complement inhibitor label in this indication, addressing substantial residual progression risk despite current standard ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4 th Complement-based Drug Development Summit. OMS906 is the company’s lead human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results